Merck Research Laboratories

What Merck Research Laboratories does

Merck Research Laboratories is the research and development division of Merck & Co., Inc. (NYSE: MRK), a research-intensive biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey. MRL operates a "One Pipeline" strategy that combines internal discovery with external innovation, running a global BD&L presence in Boston, Cambridge, South San Francisco, London, Shanghai, and Tokyo, and has invested over $65 billion in business development (licensing, acquisitions, collaborations) since 2021. The organization spans therapeutic areas including oncology, vaccines, infectious diseases, cardiometabolic and respiratory disease, immunology, neuroscience, and ophthalmology, and it operates Merck Animal Health as a separate global business unit.

The product portfolio is anchored by KEYTRUDA (pembrolizumab), the first anti-PD-1 immuno-oncology therapy, which together with KEYTRUDA QLEX generated $8.0B in Q1 2026 sales (+12% YoY). Other major assets include GARDASIL 9 (HPV vaccine), WINREVAIR (sotatercept, +88% YoY), JANUVIA (sitagliptin), CAPVAXIVE and VAXNEUVANCE (pneumococcal vaccines), ENFLONSIA (RSV), IDVYNSO (HIV), WELIREG, BRIDION, OHTUVAYRE, and animal-health products BRAVECTO and NUMELVI. Research platforms span small molecules, biologics, vaccines, antibody-drug conjugates, individualized neoantigen therapies, and macrocyclic peptides. Recent M&A (Verona Pharma 2025-10, Cidara Therapeutics 2026, Terns Pharmaceuticals pending 2026-05) and partnerships (Daiichi Sankyo, Eisai, AstraZeneca, Mayo Clinic, Google Cloud) extend the pipeline and AI capabilities.

Merck generates revenue primarily through one-time prescription pharmaceutical and vaccine sales (Q1 2026 worldwide sales of $16.3B; FY2026 guidance $65.8–$67.0B), with additional streams from animal health ($1.8B in Q1 2026) and alliance/royalty revenue (e.g., Lynparza, Lenvima, Koselugo, I-DXd). Distribution runs through authorized pharmaceutical wholesalers, hospital and clinic purchasing, retail pharmacies, government health programs in 75+ international markets, and veterinary channels, with patient-assistance programs (MerckHelps, Merck Access Program) supporting end-patient access.

Name

Merck Research Laboratories

Legal name

Merck & Co., Inc., Rahway, N.J., USA

Website

https://merck.com

Company type

Public

Founded year

1891

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merck Research Laboratories is the R&D arm of Merck & Co., Inc. (NYSE: MRK), a research-intensive biopharmaceutical company developing prescription medicines, vaccines, and animal health products across oncology, infectious disease, immunology, and cardiometabolic and respiratory disease for global markets.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Veterinary Services (54194)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Travel & Tropical Disease Vaccines (HLAIAEAE), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Veterinary Vaccines (Biologics) (HLAMAEAL), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI)

Keywords

• Biopharmaceutical research
• Immuno-oncology therapy
• Vaccine development
• Animal health products
• AI-enabled drug discovery

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure

Revenue model

1. Pharmaceutical Products: Revenue from prescription pharmaceuticals including KEYTRUDA, GARDASIL, JANUVIA, and other branded medicines. Q1 2026 pharmaceutical sales were $14.3 billion.
2. Vaccines: Revenue from vaccine products including GARDASIL 9, VAXNEUVANCE, CAPVAXIVE, ERVEBO, and pediatric vaccines. Q1 2026 vaccines contributed significantly to overall sales.
3. Animal Health: Global animal health business through Merck Animal Health offering veterinary pharmaceuticals, vaccines, and health management solutions. Q1 2026 Animal Health sales were $1.8 billion.
4. Alliance Revenue: Revenue from partnerships including Lynparza (with AstraZeneca) and Lenvima (with Eisai) where Merck shares in profits from product sales.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Merck Research Laboratories is the research and development division of Merck & Co., Inc., a research-intensive biopharmaceutical company. It discovers, develops, and commercializes prescription pharmaceuticals, vaccines, and animal health products across oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology. Key offerings include KEYTRUDA (pembrolizumab), an anti-PD-1 cancer immunotherapy, the GARDASIL HPV vaccine franchise, JANUVIA for Type 2 diabetes, and BRAVECTO for animal flea and tick control.

Product overview

Merck Research Laboratories operates as the research and development division of Merck & Co., Inc., a premier research-intensive biopharmaceutical company. The company delivers innovative health solutions through a portfolio of pharmaceutical medicines, vaccines, and animal health products. Key pharmaceutical products include KEYTRUDA (pembrolizumab), an anti-PD-1 cancer immunotherapy; WINREVAIR (sotatercept) for pulmonary arterial hypertension; JANUVIA (sitagliptin) for diabetes; IDVYNSO for HIV; and BRIDION for anesthesia. Vaccine offerings include GARDASIL 9 for HPV/cervical cancer prevention; CAPVAXIVE and VAXNEUVANCE for pneumococcal disease; ENFLONSIA for RSV; and ERVEBO for Ebola. The animal health division offers BRAVECTO for fleas/ticks and NUMELVI for canine allergies. Research efforts focus on novel modalities including individualized neoantigen therapies, antibody-drug conjugates (ADCs), macrocyclic peptides, and AI-enabled drug discovery using KERMT models and LLMs.

Differentiator

Problem solved

Functional benefit

Products and services

• KEYTRUDA (pembrolizumab) Anti-PD-1 (programmed death receptor-1) cancer immunotherapy for the treatment of various cancers including melanoma, lung cancer, bladder cancer, cervical cancer, and renal cell carcinoma. Prescribed by oncologists and administered in hospitals and cancer centers.
• KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Subcutaneous formulation of pembrolizumab for cancer treatment, offering an alternative to intravenous administration of KEYTRUDA.
• GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Recombinant HPV vaccine for prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Administered through physicians, clinics, and immunization programs.
• WINREVAIR (sotatercept) Injection for the treatment of pulmonary arterial hypertension (PAH) in adult patients.
• JANUVIA (sitagliptin) DPP-4 inhibitor for the treatment of Type 2 diabetes, prescribed by physicians and dispensed through pharmacies.
• IDVYNSO (doravirine/islatravir) Once-daily, oral, two-drug, single-tablet regimen for the treatment of certain adults with virologically suppressed HIV-1.
• ENFLONSIA (clesrovimab) Monoclonal antibody for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
• CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) Pneumococcal vaccine for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.
• VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) Pneumococcal vaccine for prevention of invasive pneumococcal disease in adults.
• PREVYMIS (letermovir) Treatment for prevention of cytomegalovirus (CMV) infection and disease in adult hematopoietic stem cell transplant recipients.
• BRIDION (sugammadex) Selective relaxant binding agent for reversal of neuromuscular blockade induced by rocuronium or vecuronium, used in surgical and anesthesia settings.
• WELIREG (belzutifan) Hypoxia-inducible factor inhibitor for treatment of Von Hippel-Lindau disease and certain renal cell carcinoma indications.
• OHTUVAYRE (ensifentrine) Inhalation suspension for maintenance treatment of COPD (chronic obstructive pulmonary disease).
• LAGEVRIO (molnupiravir) Oral antiviral medication for the treatment of COVID-19 in adults.
• BELSOMRA (suvorexant) Orexin receptor antagonist for the treatment of insomnia.
• DELSTRIGO (doravirine/lamivudine/tenofovir) Single-tablet regimen for the treatment of HIV-1 infection in adults.
• ZEPATIER (elbasvir/grazoprevir) Direct-acting antiviral for treatment of chronic hepatitis C genotype 1 or 4 infection.
• ZERBAXA (ceftolozane/tazobactam)

Quantifiable outcome

• Tuberculosis-related deaths in U.S. fell by nearly 50 percent by 1950 following streptomycin introduction
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered major, core and minor.

• Terns PharmaceuticalsmajorStrategic or Co-development Partner · 1 April 2026Merck announced agreement to acquire Terns Pharmaceuticals to expand hematology pipeline with TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with chronic myeloid leukemia (CML). Transaction expected to close in May 2026.
• Daiichi SankyomajorStrategic or Co-development PartnerCollaboration on I-DXd (ifinatamab deruxtecan) for extensive-stage small cell lung cancer. FDA granted priority review based on Phase 2 Ideate-Lung01 trial with PDUFA date of Oct. 10, 2026.
• EisaimajorStrategic or Co-development PartnerCollaboration on Lenvima (lenvatinib) for advanced renal cell carcinoma. FDA accepted supplemental application with PDUFA date of Oct. 4, 2026 for WELIREG plus Lenvima combination.
• AstraZenecamajorStrategic or Co-development PartnerAlliance on Lynparza (olaparib) for oncology. Q1 2026 alliance revenue of $341 million. Koselugo alliance revenue of $161 million including $150 million payment received for collaboration agreement amendment.
• Verona PharmamajorStrategic or Co-development PartnerAcquired in October 2025, bringing OHTUVAYRE (ensifentrine) to Merck's portfolio for respiratory diseases.
• Cidara TherapeuticsmajorStrategic or Co-development PartnerAcquisition of Cidara Therapeutics resulting in $9.0 billion charge in Q1 2026, expanding antifungal pipeline.
• Mayo CliniccoreStrategic or Co-development PartnerNew research and development collaboration announced to support AI-enabled drug discovery and precision medicine.
• Google CloudcoreTechnology or IntegrationPartnership to accelerate agentic AI enterprise transformation across Merck's operations and drug discovery processes.
• EyeBiotech LimitedminorStrategic or Co-development PartnerAcquired in 2024 with $100 million milestone charge in Q1 2025 related to EyeBio development.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Roche: Roche is a global biopharmaceutical leader with a particularly strong oncology franchise (Tecentriq, competing with KEYTRUDA) and diagnostics business. Its integrated pharma + diagnostics model and broad vaccine/therapeutic pipeline make it one of the most comparable peers to Merck.
• Novartis: Novartis is a global biopharmaceutical major with overlapping oncology, vaccines, and cardiometabolic portfolios. Its recent restructuring toward a pure-play innovative medicines company and similar scale of R&D investment make it a directly comparable peer.
• Sanofi: Sanofi competes with Merck in vaccines (influenza, pediatric), rare diseases, immunology (Dupixent), and oncology. Its global pharmaceutical scale, R&D focus, and post-consumer-health restructuring make it a closely comparable peer.
• Bristol-Myers Squibb: BMS is Merck's closest direct competitor in immuno-oncology, with Opdivo (the second anti-PD-1 to market) competing directly against KEYTRUDA across multiple tumor types. Both companies pursue similar oncology, hematology, and immunology portfolios with comparable large-cap pharma business models.
• Eli Lilly: Eli Lilly is a top-tier R&D-driven biopharmaceutical company competing with Merck in diabetes (Lilly's GLP-1 franchise competes against JANUVIA's DPP-4 mechanism) and oncology. Lilly's CEO lineage and large-pharma R&D intensity make it a strong comparable for Merck Research Laboratories.
• AstraZeneca: AstraZeneca is a direct peer through its Lynparza co-development alliance with Merck for PARP inhibitors in oncology. AZ competes in the same oncology and biopharmaceutical space and shares a similar R&D-intensive global business model.
• GSK: GSK is a direct competitor in vaccines (HPV, pneumococcal, RSV) and HIV, with a similar specialization in pharmaceutical plus vaccines. GSK's specialty medicines and vaccines focus and global footprint make it a closely comparable peer.
• Pfizer: Pfizer is one of the largest global biopharmaceutical companies, competing head-to-head with Merck across oncology, vaccines (including COVID-19), infectious diseases, and animal health (via Zoetis spinout). Both companies operate massive R&D engines and compete for the same institutional payer and prescriber relationships.

Broad incumbents

• AbbVie: AbbVie is a major biopharmaceutical company with strong oncology and immunology franchises (Imbruvica, Humira/Skyrizi/Rinvoq). While AbbVie's portfolio skews toward immunology, its scale and R&D investment make it a broad incumbent peer for Merck.
• Johnson & Johnson: J&J's Innovative Medicine division competes with Merck across oncology, immunology, infectious diseases, and neuroscience. As a larger diversified healthcare incumbent with consumer health and medtech segments, it competes broadly but with greater portfolio diversification than Merck.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/merck
• YouTubeyoutube.com/user/Merck
• Facebookfacebook.com/MerckBeWell
• LinkedInlinkedin.com/company/merck
• Instagraminstagram.com/merck

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Research Laboratories